“Pharma continues turning to AI to better understand diseases and speed up drug discovery and development,” said Noam Solomon ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

Investing in dividend stocks can be a great strategy, especially if you pick solid companies that pay reliable and high-yield ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing ...

Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the ...

"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...